NOV (NOV)
(Delayed Data from NYSE)
$15.97 USD
-0.24 (-1.48%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $15.96 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Price, Consensus and EPS Surprise
NOV 15.97 -0.24(-1.48%)
Will NOV be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for NOV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NOV
Why Nov Inc. (NOV) is a Top Growth Stock for the Long-Term
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
NOV: What are Zacks experts saying now?
Zacks Private Portfolio Services
NOV Q3 Earnings Lag Estimates, Revenues Rise Year Over Year
Nov Inc. (NOV) Reports Q3 Earnings: What Key Metrics Have to Say
Nov Inc. (NOV) Misses Q3 Earnings and Revenue Estimates
Other News for NOV
Goldman Sachs Sticks to Their Buy Rating for Novo Nordisk (0QIU)
NOV declares $0.075 dividend
Wall Street Lunch: CPI Up, But No Need For Alarms Just Yet
How Is The Market Feeling About NOV?
Bank of America Securities Sticks to Its Buy Rating for Novo Nordisk (NVO)